Outcomes in patients with metastatic bladder cancer in the USA: A retrospective electronic medical record study

Kyle Flannery; Marley Boyd; Jenny Black-Shinn; Nicholas Robert; Ashish M. Kamat

doi:10.2217/fon-2018-0654

Outcomes in patients with metastatic bladder cancer in the USA: A retrospective electronic medical record study

Kyle Flannery, Marley Boyd, Jenny Black-Shinn, Nicholas Robert, Ashish M. Kamat

Urology

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.

Original language	English (US)
Pages (from-to)	1323-1334
Number of pages	12
Journal	Future Oncology
Volume	15
Issue number	12
DOIs	https://doi.org/10.2217/fon-2018-0654
State	Published - Apr 2019

Keywords

bladder cancer
cisplatin eligible
patient outcomes
real-world utilization
treatment patterns

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2018-0654

Cite this

@article{c55fc32a656b4ebbb78d50509d4420a6,

title = "Outcomes in patients with metastatic bladder cancer in the USA: A retrospective electronic medical record study",

abstract = "Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.",

keywords = "bladder cancer, cisplatin eligible, patient outcomes, real-world utilization, treatment patterns",

author = "Kyle Flannery and Marley Boyd and Jenny Black-Shinn and Nicholas Robert and Kamat, {Ashish M.}",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

month = apr,

doi = "10.2217/fon-2018-0654",

language = "English (US)",

volume = "15",

pages = "1323--1334",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "12",

}

TY - JOUR

T1 - Outcomes in patients with metastatic bladder cancer in the USA

T2 - A retrospective electronic medical record study

AU - Flannery, Kyle

AU - Boyd, Marley

AU - Black-Shinn, Jenny

AU - Robert, Nicholas

AU - Kamat, Ashish M.

PY - 2019/4

Y1 - 2019/4

N2 - Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.

AB - Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.

KW - bladder cancer

KW - cisplatin eligible

KW - patient outcomes

KW - real-world utilization

KW - treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=85065093202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065093202&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0654

DO - 10.2217/fon-2018-0654

M3 - Article

C2 - 30942088

AN - SCOPUS:85065093202

SN - 1479-6694

VL - 15

SP - 1323

EP - 1334

JO - Future Oncology

JF - Future Oncology

IS - 12

ER -

Outcomes in patients with metastatic bladder cancer in the USA: A retrospective electronic medical record study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this